Sanofi (NASDAQ:SNY) Shares Purchased by Jones Financial Companies Lllp

Jones Financial Companies Lllp grew its stake in shares of Sanofi (NASDAQ:SNYFree Report) by 197.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,050 shares of the company’s stock after purchasing an additional 697 shares during the quarter. Jones Financial Companies Lllp’s holdings in Sanofi were worth $52,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of SNY. Rise Advisors LLC grew its holdings in Sanofi by 98.4% during the 4th quarter. Rise Advisors LLC now owns 506 shares of the company’s stock valued at $25,000 after purchasing an additional 251 shares in the last quarter. Salem Investment Counselors Inc. acquired a new stake in shares of Sanofi during the fourth quarter valued at about $27,000. Venturi Wealth Management LLC increased its position in shares of Sanofi by 163.5% during the fourth quarter. Venturi Wealth Management LLC now owns 535 shares of the company’s stock worth $27,000 after acquiring an additional 332 shares during the last quarter. Frazier Financial Advisors LLC acquired a new position in shares of Sanofi in the fourth quarter worth about $28,000. Finally, McIlrath & Eck LLC boosted its holdings in Sanofi by 143.3% in the fourth quarter. McIlrath & Eck LLC now owns 613 shares of the company’s stock valued at $30,000 after purchasing an additional 361 shares during the last quarter. Institutional investors and hedge funds own 10.04% of the company’s stock.

Sanofi Price Performance

Shares of SNY opened at $49.51 on Friday. The company has a current ratio of 1.27, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19. The firm has a market cap of $125.25 billion, a price-to-earnings ratio of 24.88, a PEG ratio of 1.53 and a beta of 0.60. Sanofi has a 52 week low of $42.63 and a 52 week high of $55.72. The stock has a 50 day moving average of $48.30 and a 200-day moving average of $48.40.

Sanofi (NASDAQ:SNYGet Free Report) last released its quarterly earnings data on Thursday, April 25th. The company reported $0.96 EPS for the quarter, hitting analysts’ consensus estimates of $0.96. The firm had revenue of $11.36 billion during the quarter, compared to the consensus estimate of $11.75 billion. Sanofi had a net margin of 10.52% and a return on equity of 26.25%. As a group, analysts forecast that Sanofi will post 4.11 EPS for the current year.

Sanofi Increases Dividend

The firm also recently disclosed an annual dividend, which was paid on Thursday, June 6th. Investors of record on Friday, May 10th were paid a dividend of $1.478 per share. This is a positive change from Sanofi’s previous annual dividend of $1.38. The ex-dividend date of this dividend was Thursday, May 9th. This represents a yield of 2.98%. Sanofi’s dividend payout ratio is 74.37%.

Analysts Set New Price Targets

A number of equities analysts have issued reports on SNY shares. TheStreet lowered Sanofi from a “b” rating to a “c” rating in a research report on Friday, February 9th. lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 27th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $55.00.

Get Our Latest Stock Analysis on SNY

Sanofi Profile

(Free Report)

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

Recommended Stories

Want to see what other hedge funds are holding SNY? Visit to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNYFree Report).

Institutional Ownership by Quarter for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with's FREE daily email newsletter.